AI drug discovery
EvolutionaryScale's biology-focused language models for drug discovery and therapeutic development will be available to AWS customers.
Tx-LLM was fine-tuned from Google's Med-PaLM 2 and created to analyze a variety of chemical or biological entities to assist with the drug-discovery pipeline.
The Israel-based company is the result of AION Labs' fifth startup challenge.
Alongside generative AI, the large database has been foundational to the development of its latest AI-powered drug discovery system.
The companies will leverage Absci's AI-enabled Integrated Drug Creation platform and the pharma giant's oncology research and development expertise.
The partners will leverage IBM’s foundation model technologies to help identify antibodies designed to target and neutralize various disease-causing agents or cells.
The company will use the funds to grow its drug-discovery pipeline and clinical AI stack.
The company will use the funds to bring its AI-enabled offerings into clinical development and advance its platform and portfolio.
The round brings the company's total raise to $93 million.
DenovAI will create an AI-powered platform to discover potential antibodies from scratch, then suggest which ones can be used as effective drugs.